SGCB and congestive heart failure: Notably, the VICTORIA trial [69] evaluated the effectiveness and safety of Vericiguat, an oral sGC stimulator, in patients with reduced left ventricular ejection fraction (LVEF) and recently decompensated chronic heart failure (CHF).